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Objective: We sought to determine the critical diameter of a peripheral non–small
cell lung cancer tumor less than which no evidence of nodal micrometastasis is
present.
Methods: Samples of 3081 lymph nodes from 181 patients with stage I peripheral
lung cancer (155 with adenocarcinoma and 26 with squamous cell carcinoma) who
had undergone complete resection with systematic lymphadenectomy were used in
the study. In the samples immunohistochemical staining for cytokeratin was per-
formed. The expression of vascular endothelial growth factor (VEGF) at primary
sites was also immunohistochemically assessed.
Results: Nodal micrometastasis was detected in 44 patients. The mean tumor sizes
were 2.2 ± 1.3 cm (range, 1.0-7.0 cm) in nodal micrometastasis–positive adenocar-
cinoma, 2.1 ± 0.9 cm (range, 0.5-6.0 cm) in nodal micrometastasis–negative ade-
nocarcinoma, 4.8 ± 2.3 cm (range, 2.2-10.0 cm) in nodal micrometastasis–positive
squamous cell carcinoma, and 3.2 ± 2.1 cm (range, 0-9.0 cm) in nodal micrometas-
tasis–negative squamous cell carcinoma. The tumor size in the nodal micrometas-
tasis–positive group tended to be greater than that in the nodal micrometastasis–
negative group in squamous cell carcinomas, but there was no significant difference
in adenocarcinomas. Nodal micrometastasis was not found in patients with squa-
mous cell carcinoma of 2.0 cm or less in diameter. However, nodal micrometasta-
sis was found in 20% (19/95) of the patients with adenocarcinoma of 1.1 to 2.0 cm
in diameter and even in 4 of 11 patients with adenocarcinoma of 1.0 cm or less.
Among the patients with nodal micrometastasis, survival of patients with vascular
endothelial growth factor overexpression was worse than that of patients without it.
The survival of patients with nodal micrometastasis without vascular endothelial
growth factor overexpression was comparable with that of patients without nodal
micrometastasis.
Conclusion: A limited surgical intervention without lymphadenectomy is validated
for squamous cell carcinoma of 2.0 cm or less without pleural involvement. In ade-
nocarcinoma the tumor size itself is not a reliable guide for nodal micrometastasis
status. In patients with nodal micrometastasis with vascular endothelial growth fac-
tor overexpression, the risk of systemic disease should be considered.
From the Departments of Thoracic Surgerya
and Pathology,b Kanazawa University,
School of Medicine, and the Department of
Thoracic Surgery,c Ishikawa Prefectural
Central Hospital, Kanazawa, Japan.
Received for publication April 16, 2001;
revisions requested May 23, 2001; revisions
received May 29, 2001; accepted for publi-
cation June 1, 2001.
Address for reprints: Yasuhiko Ohta, MD,
Department of Thoracic Surgery, Kanazawa
University, School of Medicine, Takara-
machi 13-1, Kanazawa 920-8641, Japan (E-
mail: yohta@med.kanazawa-u.ac.jp).
J Thorac Cardiovasc Surg 2001;122:900-6
Copyright © 2001 by The American
Association for Thoracic Surgery
0022-5223/2001 $35.00 + 0 12/1/117626
doi:10.1067/mtc.2001.117626
Can tumor size be a guide for limited surgical
intervention in patients with peripheral non–small cell
lung cancer? Assessment from the point of view of nodal
micrometastasis
Yasuhiko Ohta, MDa,c
Makoto Oda, MDa
Jian Wu, MDa
Yoshio Tsunezuka, MDa
Minato Hiroshi, MDb
Akitaka Nonomura, MDb
Go Watanabe, MDa
Ohta et al General Thoracic Surgery
TX
ET
CP
B
A
CD
CH
D
G
TS
ED
IT
O
RI
A
L
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 5   901
The presence of nodal metastasis has a deci-sive meaning for the postoperative outcomeof patients with lung cancer. Of importance,recent studies have revealed that the presenceof microdissemination of cancer cells inlymph nodes has a significantly negative
effect on survival of patients with lung cancer despite sys-
temic lymphadenectomy, generally resulting in distant
relapse, even after a curative operation.1-4 A plausible expla-
nation for this matched interrelation between microdissem-
ination of cancer cells in lymph nodes and dismal clinical
outcome after complete resection is that the small amount of
cancer cells detected as a single or clustered formation in
nodes is a premanifestation state of metastasis, and some of
them have a risk of systemic disease. Recently, with the
advent of computed tomography (CT) scanning for screen-
ing for lung cancer, thoracic surgeons have often begun to
encounter cases of small-sized peripheral lung cancer.
However, we do not yet know whether the primary lung
tumor size can be used as a basis for the selection of limited
surgical intervention from the point of view of nodal
micrometastasis (NM). Moreover, identification of micro-
metastasis with a risk of development of systemic disease is
necessary to put forward adjuvant therapies in patients with
early stage lung cancer. This study was undertaken to ascer-
tain whether there is a critical diameter of a peripheral
non–small cell lung cancer (NSCLC) tumor less than which
no evidence of NM is found.
Methods
Patients
A total of 3081 lymph nodes were obtained from 181 randomly
selected patients with stage I NSCLC of the peripheral type who
had undergone complete resection with systematic lymphadenec-
tomy at Kanazawa University Hospital from 1986 to 1996. The
181 patients included 94 men and 87 women with a mean age of
63.7 ± 9.6 years (range, 38-84 years; median, 65 years). The patho-
logic types were 155 adenocarcinomas and 26 squamous cell car-
cinomas. According to the TNM classification, 148 patients had
tumors of 3 cm or less in diameter (T1 N0 M0 disease) and 33
patients had tumors greater than 3 cm (T2 N0 M0 disease). Table
1 shows the basic clinical features of the patients. Informed con-
sent was obtained from all patients for the use of both primary
tumor and lymph node samples.
Immunohistochemistry for Detection of
Micrometastasis
The existence of cancer cells within lymph nodes was examined by
using immunohistochemical staining for cytokeratin, as described
previously.5 In brief, after deparaffinization of 4-µm thick paraffin
sections obtained from lymph node samples, the sections were
boiled for 5 minutes in 0.01 mol/L sodium citrate solution (pH 6.0)
in a microwave oven 3 times. Endogenous peroxidase was blocked
by treatment with 0.3% hydrogen peroxide in methanol for 15
minutes. The sections were incubated with normal goat serum
diluted 10-fold with phosphate-buffered saline solution for 15
minutes for blocking. After incubation, the sections were reacted
with anti-AE1/AE3 antibody (DAKO, Carpinteria, Calif) that had
been diluted 50-fold with phosphate-buffered saline solution for 1
hour at room temperature, and then they were reacted with biotin-
labeled goat anti-mouse immunoglobulin (DAKO) for 2 hours.
After adding avidin-biotin-peroxidase complex, color was devel-
oped with 3-3 diaminobenzidine (Sigma Chemical Co, St Louis,
Mo) and 0.03% hydrogen peroxide. Counterstaining was done
with hematoxylin and eosin. In this study both single and clustered
tumor cells with a size of not more than 2 mm were defined as
micrometastases, taking into consideration morphologic fea-
tures.2,6 Positivity was blindly evaluated by 2 independent
observers, including a pathologist without knowledge of the clini-
copathologic factors.
Immunohistochemical Assessment of Vascular
Endothelial Growth Factor
The expression of vascular endothelial growth factor (VEGF) in
cancer cells at the primary site was also immunohistochemically
assessed by using the labeled streptavidin-biotin method, as
described previously.5,7,8 For the primary antibody, we used the
anti-VEGF polyclonal antibody (Santa Cruz Biotechnology Inc,
Heidelberg, Germany) diluted 100-fold. Paraffin-embedded sec-
tions of the invasive edges of the tumors were reacted with the anti-
body for 2 hours at room temperature. The second antibody used
was biotin-labeled goat anti-mouse immunoglobulin (DAKO). A
tumor with more than 50% positive staining area of cancer cells
was defined as a VEGF-overexpressing tumor.5,8
Statistics
The association between variables was analyzed with the χ2 test.
The Mann-Whitney U test for difference in the mean values was
used for comparison of nominal data. Survival curves were
obtained by the Kaplan-Meier method and compared by the log-
rank test. NM, age (≥65 vs <65 years), sex, T factor (T1 vs T2),
pathologic type, differentiation of tumors (poorly vs moderately or
well), blood vessel invasion, lymphatic vessel invasion, and VEGF
were included in the assessment of prognostic indicators. Both uni-
variate and multivariate analyses were performed with the Cox
proportional hazard model. Values are given as means ± SD. The
data were analyzed with a statistical software package (StatView;
Abacus Concepts, Inc, Berkeley, Calif).
Results
Positive staining for AE1/AE3 was confirmed in both nor-
mal epithelial and tumor cells in primary sites in all cases.
CK-positive cancer cells were detected in lymph nodes in 44
(24.3%) patients. Most of the disseminated cancer cells
showed clustered formation at the edges of the nodes.
Thirty-two of these 44 patients had micrometastasis in a sin-
gle nodal station, and 12 patients had micrometastasis at
multiple levels. On the basis of the sites of affected lymph
nodes, 19 patients had N1 disease, and 25 patients had N2
disease. As shown in Table 1, there were no significant dif-
ferences in the percentages of patients with and without NM
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according to age, sex, location of the primary tumor (right
vs left, upper lobe vs lower lobe), and pathologic type (ade-
nocarcinoma vs squamous cell carcinoma). In adenocarci-
noma the incidence of NM was significantly higher in the
patients with poorly differentiated tumors than in those with
well or moderately differentiated tumors (P = .002). The
incidence of NM was significantly higher in tumors with
lymphatic vessel invasion than in tumors without it (P =
.006). In squamous cell carcinoma the T factor affected the
NM incidence (P = .0344). Of 155 patients with adenocar-
cinoma, 34 (21.9%) had NM, and of 26 patients with squa-
mous cell carcinomas, 10 (38.5%) had NM. NM outside the
regional lymph nodes (ie, skipping metastasis) was detected
in 25 (56.8%) patients. In patients with the primary tumor in
an upper lobe, NM was mainly detected in the upper medi-
astinal area. However, in 3 of 18 patients with the primary
tumor in the right upper lobe, spread of NM to the lower
mediastinal area (subcarinal nodal involvement) was found.
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In patients with tumors in the left lower lobe, NM was
mainly found in the lower mediastinal area. In 4 of 6
patients with tumors in the right lower lobe, NM was found
in the upper mediastinal area.
The mean tumor sizes, according to NM status and
pathologic type, were 2.2 ± 1.3 cm (range, 1.0-7.0 cm) in
NM-positive adenocarcinoma, 2.1 ± 0.9 cm (range, 0.5-6.0
cm) in NM-negative adenocarcinoma, 4.8 ± 2.3 cm (range,
2.2-10.0 cm) in NM-positive squamous cell carcinoma, and
3.2 ± 2.1 cm (range, 0-9.0 cm) in NM-negative squamous
cell carcinoma. The mean primary tumor size in the NM-
positive group tended to be greater than that in the NM-neg-
ative group in squamous cell carcinomas (P = .0651), but no
significant difference was found in adenocarcinomas (P =
.9655). In patients with squamous cell carcinoma of 2.0 cm
or less in diameter, NM was not found (0/6). However, of
the 20 patients with squamous cell carcinoma of more than
2.0 cm in diameter, 10 (50%) patients had micrometastasis.
TABLE 1. Correlation of clinicopathologic features with modal micrometastasis (NM)
Total (n = 181) Adenocarcinoma Squamous cell carcinoma
Factors NM(+) NM(–) P value NM(+) NM(–) P value NM(+) NM(–) P value
Patients 44 137 34 121 10 16
Sex .8918 .5397 .1971
Male 23 70 14 54 9 16
Female 21 67 20 67 1 0
Mean ±SD age (y) 64.5 ± 8.6 63.6 ± 9.8 .5921 63.3 ± 8.6 63.2 ± 9.9 .9053 68.6 ± 7.7 66.1 ± 8.5 .5747
T factor .0552 .9751 .0344
T1 32 117 30 107 2 10
T2 12 20 4 14 8 6
Differentiation .0045 .0020 .9373
Well-moderate 34 127 26 114 8 13
Poor 10 10 8 7 2 3
Location of primary tumor
Right 28 96 .4239 21 87 .1809 7 9 .4832
Left 16 41 13 34 3 7
Upper lobe 30 82 .6618 25 73 .2780 5 9 .6217
Middle lobe 2 12 2 11 0 1
Lower lobe 12 43 7 37 5 6
Lymphatic vessel invasion .0060 .0025 .8989
Positive 25 44 21 38 4 6
Negative 19 93 13 83 6 10
Blood vessel invasion .0833 .0590 .8506
Positive 20 41 16 34 4 7
Negative 24 96 18 87 6 9
TABLE 2. Primary tumor size and NM status
Adenocarcinoma (n = 155) Squamous cell carcinoma (n = 26)
≤1.0 cm 1.1-2.0 cm ≥2.1 cm ≤1.0 cm 1.1-2.0 cm ≥2.1 cm
NM positive (n) 4 19 11 0 0 10
NM negative (n) 7 76 38 2 4 10
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The incidence of NM in patients with adenocarcinoma of
1.1 cm to 2.0 cm in diameter was 20% (19/95). Of the 11
patients with adenocarcinoma of 1.0 cm or less in diameter,
4 had NM (Table 2). Primary tumor size was 1.0 cm in all 4
cases, and NM was detected at a single level. In 3 of the 4
patients, the affected nodal station was localized within the
segmental area, and all 4 patients survived after standard
resection (lobectomy) plus systematic lymph node dissec-
tion (Table 3).
There was no significant difference between survivals of
patients with adenocarcinomas and those with squamous
cell carcinomas (P = .324). The 5- and 10-year survivals of
patients were 54.5% and 40.2%, respectively, in the NM-
positive group (n = 44) and 82.4% and 74.8%, respectively,
in the NM-negative group (n = 137; P < .0001, Figure 1).
The immunohistochemical staining for VEGF was per-
formed in 177 patients in total. VEGF antigens were mainly
identified in the cytoplasm of tumor cells and vascular
endothelial cells, as we previously reported.5,8 The percent-
age of patients with VEGF overexpression was 57.6%
(102/177) in total. The percentage of patients with VEGF
overexpression in the NM-positive group was significantly
higher than that in the NM-negative group (74.4% vs
52.2%, P = .0165). Among the patients with NM, survival
of patients with VEGF overexpression was worse than that
of patients without it (P < .0001). However, the survival of
patients with NM without VEGF overexpression was almost
equivalent to that of patients without NM (Figure 2). Among
TABLE 3. Patients with peripheral adenocarcinoma of 1.0 cm in diameter
Nodal station
Primary Location of NM Lymphatic Blood
Patient tumor size of primary (No. of vessel vessel Outcome
No. Sex Age (y) (cm) tumor positive node) invasion invasion (mo)
1 Female 69 1.0 RUL 13 (1) Negative Negative Alive (163)
2 Male 59 1.0 LUL 12 (1) Negative Negative Alive (100)
3 Female 55 1.0 RUL 11 (1) Positive Negative Alive (99)
4 Male 59 1.0 RUL 1 (1) Positive Positive Alive (87)
RUL, Right upper lobe; LUL, left upper lobe.
Figure 1. Kaplan-Meier survival plots for 181 patients with peripheral stage I NSCLCs subdivided according to
NM status. The difference in survival between the NM-positive group (n = 44) and the NM-negative group (n =
137) was significant (P < .0001).
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various prognostic indicators assessed, age, sex, T factor,
blood vessel invasion, NM, and VEGF had statistically sig-
nificant values. As a result of multivariate analysis, T factor,
NM, VEGF, and sex retained a significant independent
prognostic effect on overall survival (Table 4).
Discussion
There seems to be general agreement that relapse after com-
plete resection of a primary tumor in the early stage is a con-
sequence of micrometastases that are present at the time of
operation. A number of researchers have actually found the
existence of small amounts of disseminated cancer cells in
some distant organs, including lymph nodes, even in cases in
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which no metastasis was found by conventional examina-
tions. Although the metastatic ability of these disseminated
cancer cells is not fully understood, after the event of intrava-
sation, most cancer cells have been found to undergo apopto-
sis or to remain in a dormant state, and very few cancer cells
eventually succeed in the formation of established metasta-
sis.9,10 In lymphatic systems, however, the movement of can-
cer cells is relatively slow through nodal stations. This less
stressful situation of slow lymphatic flow may allow cancer
cells a chance at the formation of nodal metastasis.10 To char-
acterize disseminated occult cancer cells in lymph nodes, we
previously studied the expression of some metastasis-associ-
ated markers, including angiogenesis and lymphangiogenesis
Figure 2. Kaplan-Meier survival plots for stage I NSCLCs subdivided according to NM status and VEGF expres-
sion level. A tumor was included in the VEGF-overexpressing group if the positive staining area in tumor cells
was more than 50%. Among the patients with NM, survival of the patients with VEGF overexpression was sig-
nificantly worse than that of the patients without it (P < .0001).
TABLE 4. Multivariate analysis by means of Cox proportional hazard regression model
Characteristics
Factors Unfavorable Favorable P value Hazard ratio (95% CI)
NM Positive Negative .0004 2.874 (1.604-5.149)
T factor T2 T1 .0023 2.976 (1.477-5.998)
VEGF* High Low .0049 2.604 (1.337-5.071)
Sex Male Female .0083 2.507 (1.267-4.960)
Blood vessel invasion Positive Negative .0558 1.806 (0.985-3.309)
Age (y) ≥65 <65 .3626 0.742 (0.396-1.392)
*A tumor was included in the VEGF-overexpressing group if the positive staining area in tumor cells was greater than 50%.
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stimulators, such as VEGF, VEGF-C, and nm23, in the pri-
mary site, and we found a significant association of these
markers with NM and poor prognosis in NSCLC.5 Although
the presence of micrometastases does not affect cancer stag-
ing systems, we consider that patients with these disseminated
cancer cells within lymph nodes belong to a high-risk group
of recurrence, and detection of NM by using the immunohis-
tochemical method used here should enable better stratifica-
tion of patients with lung cancer in early stages of the disease.
Because of the spreading use of CT examinations and
high-resolution CT, the detection rate of small-sized periph-
eral lung cancer appears to be increasing. If there exists a crit-
ical tumor diameter less than which no lymph node
metastasis will be found, it would be possible to treat small-
sized peripheral lung cancer with minimally invasive proce-
dures without systematic lymphadenectomy and with less
concern about relapse. We previously performed a retrospec-
tive study on nodal status on the basis of the results of con-
ventional histopathologic examination with hematoxylin and
eosin staining.11 In that study the incidence of nodal metas-
tasis in 524 patients with NSCLC with clinical stage I disease
was 22%. When stratified by histologic type, the frequency of
nodal metastasis was 0% in tumors of less than 1.0 cm in
diameter and 7.4% in those of 1.1 to 2.0 cm in diameter in
squamous cell carcinoma. In adenocarcinoma the frequency
was 0% in tumors of less than 1.0 cm and 20.8% in tumors of
1.1 to 2.0 cm in diameter. On the basis of these results, we
suggested that systematic lymphadenectomy is dispensable
in patients with peripheral squamous cell carcinoma of 2.0
cm or less in diameter and also in patients with adenocarci-
noma of 1.0 cm or less in diameter. On the basis of the con-
ventional histopathologic examination, Asamura and
colleagues12 found that the prevalence of nodal metastasis
was relatively high, despite the small size of the primary
tumor. According to their report, the frequencies of nodal
involvement in patients with tumors of 2.0 cm or less in
diameter were 6.3% in squamous cell carcinoma and 21.1%
in adenocarcinoma. By meticulous examination of nodal
involvement, they also found a low frequency of nodal
involvement in squamous cell carcinoma of 2.0 cm or less in
diameter. In the present study we assessed the spread of
micrometastasis in patients in whom a diagnosis of N0 had
been made on the basis of the results of conventional exami-
nation. Our findings concerning NM support the claim that a
tumor diameter of 2.0 cm or less is a reliable criterion for
selection of limited surgical intervention without lymph-
adenectomy for patients with squamous cell carcinoma. With
regard to adenocarcinoma, however, the frequency of NM
(21.7% [23/106]) was high in patients in whom a diagnosis of
N0 was made by means of conventional methods, even if the
diameter of the primary tumor was 2.0 cm or less. In addition,
the spread of NM was sometimes beyond the regional area,
and so-called skipping metastasis was frequently found.
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Notably, adenocarcinoma of 1.0 cm or less in diameter also
retained a risk of NM (4/11) in our series. Although previous
studies on the basis of conventional hematoxylin and eosin
staining have suggested the propriety of limited surgical
intervention without lymphadenectomy for patients with ade-
nocarcinoma of 1.0 cm or less in diameter,11,13 our results
indicated that a more prudent stance should be taken for ade-
nocarcinoma. Nevertheless, NM was detected at a single
level in all of 4 patients with adenocarcinoma of 1.0 cm in
diameter, and the affected nodal area was localized within
segmental nodes in 3 patients. The propriety of the criterion
of 1.0 cm or less in adenocarcinoma warrants further study
with a larger number of samples. In a cohort of patients with
peripheral adenocarcinoma of 2 cm or less in diameter, we
previously found that there was no NM in patients with local-
ized bronchioloalveolar carcinoma or localized bronchi-
oloalveolar carcinoma with foci of collapse of alveolar
structure.14 Some patients with small-sized peripheral adeno-
carcinoma may benefit from limited surgical intervention if a
reliable preoperative diagnostic method for the new histo-
logic classification proposed by Noguchi and colleagues15 is
developed.
The efficacy of systemic lymphadenectomy for NSCLC
has been an issue of controversy. Among those who are
against its therapeutic value, Izbicki and his colleagues16,17
found no prognostic advantage of radical lymphadenectomy
in randomized controlled clinical trials with a cohort of
patients with NSCLC. Sugi and coworkers18 also argued
against the necessity of radical lymphadenectomy for
peripheral small-sized NSCLC of less than 2.0 cm in diam-
eter on the basis of a prospective randomized study. On the
other hand, although mainly based on nonrandomized com-
parison, some investigators uphold the therapeutic value of
radical systematic lymphadenectomy.19-21 Although contro-
versy over the therapeutic value of lymphadenectomy
remains, it is thought that standard resection, such as lobec-
tomy plus radical lymphadenectomy, is the most reliable
way to remove the local disease in patients with a risk of
nodal involvement in the hilar or mediastinal area. Holding
a risk of nodal involvement, some surgeons have advocated
the usefulness of limited surgical intervention with minimal
lung parenchymal resection. In proper selection of patients,
although the final surgical results should be assessed in the
long term, sublobar resections, such as segmentectomy with
intraoperative exploration of nodal metastasis, have been
reported to achieve comparable prognostic results compared
with the results of lobectomy.22-26
Clearly, our results enlightened the evidence that the pri-
mary tumor size itself is not a reliable guide for NM status
in adenocarcinoma. Therefore, a standard operation with
systematic lymphadenectomy might still be a principal and
a favorable surgical procedure for adenocarcinoma of more
than 1.0 cm in diameter.
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Considering the fact that some patients still experienced
relapse, mainly distant metastasis, despite complete resec-
tion of the primary tumor and systematic lymphadenectomy,
discrimination of patients with a high risk of systemic dis-
ease also seems to be an important issue for the appropriate
selection of patients for limited surgical intervention. From
the results of this study, assessment of VEGF expression at
the primary site appears to be useful for better stratification
of patients with NM. Although the efficacy of adjuvant
chemotherapy has not been fully substantiated, noncyto-
toxic therapies, including antiangiogenic therapies, may be
effective therapeutic modalities.
Although the relations should be further explored in
larger data sets, the following conclusions can be made from
our study of the spread of NM in peripheral NSCLC.
Limited surgical intervention without lymphadenectomy
appears to be validated for squamous cell carcinoma of 2.0
cm or less in diameter. In adenocarcinoma tumor size itself
is not a reliable guide for NM status. Because the presence
of NM is an important prognostic indicator in NSCLC, we
need to further examine the biologic behavior of small-sized
adenocarcinoma for the proper selection of patients for lim-
ited surgical intevrention.
We thank Hiroyuki Nakamura, MD, DMedSc (Department of
Public Health), for his review of statistical analysis and for help
with manuscript preparation.
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